TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07893106: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight

Sponsor: Ascletis Pharma (China) Co., Limited · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 86 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07893106 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07893106 Rescue Dossier →